Zynex Inc. filings document the regulatory record of a medical technology company that develops and sells non-invasive devices for pain management, rehabilitation, and patient monitoring. Its periodic reports and current reports have covered operating results, liquidity, billing and reimbursement matters, compliance risks, governance changes, and material events affecting the company and its subsidiaries.
Recent filings also document Zynex's Chapter 11 reorganization and public-company status changes. The record includes 8-K disclosures on bankruptcy proceedings, plan amendments and confirmation, Nasdaq delisting and OTC trading status, material agreements with government authorities, the conclusion of an SEC investigation without a recommended enforcement action, and board actions. A Form 15 reports termination or suspension of Exchange Act registration duties after the plan became effective, the prior common stock was cancelled, and new common stock was issued to the plan sponsor.
Zynex Inc. director Barry D. Michaels reported a disposition of 80,001 shares of common stock back to the company, leaving him with zero shares. The transaction was recorded at a price of $0.00 per share and is classified as a disposition to the issuer.
According to the confirmed Chapter 11 reorganization plan, all outstanding Zynex common shares, stock awards, options, warrants, and related rights were cancelled for no consideration when the plan became effective on March 26, 2026, resulting in no recovery for existing equity holders.
Zynex Inc director Joshua R. Disbrow reported the cancellation of his equity holdings following the company’s Chapter 11 reorganization. On March 26, 2026, a total of 12,499 shares of restricted common stock and 89,501 shares of common stock were disposed of back to the issuer for no consideration, leaving zero shares reported as held.
This followed confirmation of Zynex’s Third Amended Chapter 11 Plan by the U.S. Bankruptcy Court for the Southern District of Texas on March 19, 2026, under which all outstanding common shares, equity awards, options, warrants and related rights were cancelled with no recovery under the plan.
Zynex Inc director Michael D. Cress reported disposing of all his common stock holdings back to the company as part of its Chapter 11 restructuring. The filing shows issuer dispositions of 12,499 shares of restricted common stock and 82,501 shares of common stock, leaving him with zero shares.
According to the confirmed reorganization plan, all outstanding Zynex common shares, equity awards, options, warrants and related rights were cancelled for no consideration when the plan became effective on March 26, 2026. Existing shareholders received no recovery under this court-approved plan.
Zynex, Inc. has emerged from Chapter 11 protection after a court confirmed reorganization plan became effective on March 26, 2026. As part of the plan, all previously issued equity, including existing common stock and equity awards, was cancelled and extinguished, and 1,000 new common shares were issued to Altivera Medical Holdings LLC, which now owns 100% of the company.
The company entered a new $10.0 million senior secured term loan maturing in 2034, which will convert into common stock once specified payments under a non-prosecution agreement are completed or at maturity. Zynex’s prior $22.3 million DIP facility and $60.0 million convertible notes were discharged. Amended articles now authorize up to 1,000,000 common shares, and new bylaws reset shareholder voting and governance procedures alongside board changes at both the sponsor and company level.
Zynex, Inc. reports that a U.S. bankruptcy court has entered a confirmation order approving its Chapter 11 reorganization plan and disclosure statement. Once conditions are met and the plan becomes effective, all existing equity interests, including the current 30,781,021 common shares, will be cancelled, released and extinguished. Approximately 1,000 new common shares will be issued to an entity owned by the DIP lenders as the plan sponsor, alongside $10 million of takeback debt. The company cautions that trading in its securities is highly speculative and expects existing equity holders to experience a significant loss on their investment if the restructuring transactions are implemented.
Zynex, Inc. reported that the U.S. Securities and Exchange Commission has concluded its investigation and, based on information available, does not intend to recommend an enforcement action against the company. This investigation had been previously disclosed.
The company also reminds investors that its common stock was delisted from Nasdaq following the commencement of voluntary Chapter 11 cases and now trades on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities during the Chapter 11 process is highly speculative, as the restructuring is expected to cause equity holders to experience a significant loss and the common stock is likely to be cancelled.